Guizhou Sanli Pharmaceutical Co Ltd (603439) - Total Liabilities
Based on the latest financial reports, Guizhou Sanli Pharmaceutical Co Ltd (603439) has total liabilities worth CN¥1.30 Billion CNY (≈ $190.23 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Guizhou Sanli Pharmaceutical Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Guizhou Sanli Pharmaceutical Co Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Guizhou Sanli Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Guizhou Sanli Pharmaceutical Co Ltd assets under control.
Guizhou Sanli Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guizhou Sanli Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Marimaca Copper Corp
TO:MARI
|
Canada | CA$5.59 Million |
|
JOST Werke AG
XETRA:JST
|
Germany | €1.27 Billion |
|
MFA Financial Inc
NYSE:MFA
|
USA | $11.88 Billion |
|
SG Fleet Group Ltd
AU:SGF
|
Australia | AU$2.91 Billion |
|
Shenzhen Tellus Holding Co Ltd
SHE:000025
|
China | CN¥677.71 Million |
|
Asiainfo Security Technologies Corp. A
SHG:688225
|
China | CN¥5.68 Billion |
|
Jaya Real Property Tbk
JK:JRPT
|
Indonesia | Rp4.48 Trillion |
|
Hubei Tech Semiconductors Co
SHE:300046
|
China | CN¥106.72 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Guizhou Sanli Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Guizhou Sanli Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guizhou Sanli Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual total liabilities of Guizhou Sanli Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.60 Billion ≈ $233.76 Million |
+31.90% |
| 2023-12-31 | CN¥1.21 Billion ≈ $177.22 Million |
+109.39% |
| 2022-12-31 | CN¥578.40 Million ≈ $84.64 Million |
+55.10% |
| 2021-12-31 | CN¥372.93 Million ≈ $54.57 Million |
+34.67% |
| 2020-12-31 | CN¥276.91 Million ≈ $40.52 Million |
+247.35% |
| 2019-12-31 | CN¥79.72 Million ≈ $11.67 Million |
+35.84% |
| 2018-12-31 | CN¥58.69 Million ≈ $8.59 Million |
-36.26% |
| 2017-12-31 | CN¥92.07 Million ≈ $13.47 Million |
+5.30% |
| 2016-12-31 | CN¥87.44 Million ≈ $12.79 Million |
+1.50% |
| 2015-12-31 | CN¥86.14 Million ≈ $12.60 Million |
-38.33% |
| 2014-12-31 | CN¥139.67 Million ≈ $20.44 Million |
+7.01% |
| 2013-12-31 | CN¥130.52 Million ≈ $19.10 Million |
-- |
About Guizhou Sanli Pharmaceutical Co Ltd
Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonic, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, includi… Read more